Toni Choueiri: Talazoparib with or without enzalutamide in mCRPC

Toni Choueiri shared on X:

”JUST IN: HUGE NEWS ==> OS benefit from TALAPRO-2 study of PARP inh.

Talazoparib + Enzalutamide (Enza) vs. Enza in metastatic castrate-resistant prostate cancer (mCRPC). Results in all comers, as well as HRR gene-mutated mCRPC! Original results + for rPFS and published in The Lancet.

Congrats to PI Neeraj Agarwal, the team and the patients!”

Alessandro Samuelly, Medical oncologist at the University of Turin, shared a post by Toni Choueiri on X, adding:

” While this is somewhat good news, therapeutic anticipation has heavy impacts on QoL and economic burdens. These trials don’t provide subsequent standard of care treatment. I’m sure we’ll see that around 30-50% of patients will never receive a PARP inhibitor in the control group.”

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Authors: Arun A Azad, Joan Carles, Andre P Fay, Nobuaki Matsubara, Daniel Heinrich, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G Healy, Nicola Di Santo, Fabian Zohren, Karim Fizazi.

Additional information.

Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.